Gem Aromatics Limited has informed the Exchange about Investor Presentation
GEMAROMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Gem Aromatics Limited, a manufacturer and exporter of essential oils and aromatic chemicals, reported Q4FY26 results with sequential recovery in revenue to Rs 112 crore standalone (up 34% QoQ) and Rs 110 crore consolidated (up 40% QoQ). Gross margins improved significantly to 23.4% standalone and 30.5% consolidated from 18.4% and 25.2% respectively in Q3FY26. EBITDA margins also improved to 13.4% standalone and 14.2% consolidated. Consolidated PAT turned positive at Rs 1 crore from a loss of Rs 5 crore in Q3FY26. The improvement was driven by better price realization, improved volumes, operating leverage, and healthier product mix. The Dahej greenfield facility (invested ~Rs 270 crore) has been capitalized, with commercial production of GEM Cool 5 cooling agents and Safranal commencing from February 2026. However, the phenol derivatives business faces near-term challenges due to elevated phenol prices and supply volatility from geopolitical issues. Year-on-year, revenue declined 45% and PAT fell 96% due to macro headwinds. The company has 10,871 MTPA total installed capacity across its three facilities.
The sequential margin improvement signals operational recovery and better cost management, which could be positive for the stock. However, investors should note the significant year-on-year decline in performance, higher depreciation from Dahej capex capitalization impacting near-term profitability, and supply chain uncertainties in the phenol derivatives segment. The company's expansion into high-value specialty molecules like cooling agents and citral chemistry could support future growth once ramp-up is complete.